YC W24
Granza Bio
Reprogramming Immunity for Target-Specific Medicines
About
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
Founders
- Ashwin Jainarayanan
Family Office Investors
4 deals trackedAltss has tracked family office activity in Granza Bio. Investors shown are from our private markets database.
- Eli Brown (Angel)
- Joel Meyer (Angel)
- Will Olsen (Angel)
- +1 more investors
Industry & Focus
HealthcareTherapeuticsSynthetic BiologyBiotechOncology